Administrative Core

行政核心

基本信息

  • 批准号:
    8464019
  • 负责人:
  • 金额:
    $ 3.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-03-17 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

This Program Project will be formally aligned under the Linus Pauling Institute (LPI) at Oregon State University (OSU), Housing of the Program Project under LPI provides a pre-existing organizational structure for administration of the grant, and for promoting scientific interaction with other research centers on campus with allied research interests. The latter include the NIEHS-funded Environmental Health Sciences Center (EHSC) and the Center for Genome Research and Biocomputing (CGRB). This alignment also provides direct access to the highest levels of university administration. Roderick Dashwood, the Principal Investigator of the Program Project, currently serves as Chief of the Cancer Chemoprotection Program in LPI, Leader of the EHSC Environmental Mutagenesis & Carcinogenesis research core, and Professor of Environmental & Molecular Toxicology. Dr. Dashwood's oversight of Core B will be carried out with assistance from Barbara McVicar, senior office specialist and Assistant to the Director and Cathy Abney, accounts manager. Core B will provide liaison with NIH in all application and reporting responsibilities, including compiling and submission of all reports and non-competing renewals required by NIH, and obtaining approvals of human subjects and vertebrate animals. This core will directly administer the budgets for all three Projects, and for the Epigenetic/Translational Biomarkers (ETB) Core, coordinate regularly scheduled Project meetings, and organize all activities associated with the annual External Advisory Committee (EAC) meetings. The EAC consists of Dr. Johanna W. Lampe, Fred Hutchinson Cancer Research Center, Dr. William Helferich, University of Illinois, and Dr. Paul Limburg, Mayo Clinic. This committee of distinguished scientists has already functioned to guide the investigators in the preparation of this competing continuation, with reviews and helpful suggestions pertaining to specific Project elements, according to their areas of expertise. In the future, EAC members will assess research progress, advise the PI and Project Leaders on how the Program Project may best respond to advances in the field of cancer chemoprevention, and discuss with OSU research administration the university commitments that may be necessary to facilitate such responses.
该计划项目将正式调整下莱纳斯鲍林研究所(LPI)在俄勒冈州州立大学(OSU),住房的计划项目下LPI提供了一个预先存在的组织结构管理的补助金,并促进与其他研究中心在校园内与盟军的研究兴趣的科学互动。后者包括NIEHS资助的环境健康科学中心(EHSC)和基因组研究和生物计算中心(CGRB)。这种对齐也提供了直接进入大学管理的最高水平。 Roderick Dashwood是该项目的主要研究员,目前担任LPI癌症化学保护项目负责人,EHSC环境诱变和致癌研究核心负责人,以及环境与分子毒理学教授。达什伍德博士对核心B的监督将在高级办公室专家兼主任助理芭芭拉·麦克维卡尔和客户经理凯西·阿布尼的协助下进行。 核心B将在所有申请和报告职责中与NIH保持联络,包括编写和提交NIH要求的所有报告和非竞争性更新,以及获得人类受试者和脊椎动物的批准。该核心将直接管理所有三个项目和表观遗传/转化生物标志物(ETB)核心的预算,协调定期计划的项目会议,并组织与年度外部咨询委员会(EAC)会议相关的所有活动。 EAC由Johanna W博士组成。Lampe,Fred哈钦森癌症研究中心,伊利诺伊大学的William Helferich博士和马约诊所的Paul林布尔格博士。这个由杰出科学家组成的委员会已经发挥作用,指导研究人员准备这一竞争性的延续,根据他们的专业领域,对具体的项目要素进行审查和提出有益的建议。在未来,EAC成员将评估研究进展,建议PI和项目负责人如何最好地应对癌症化学预防领域的进展,并与俄勒冈州立大学研究管理部门讨论可能需要促进这种反应的大学承诺。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roderick H Dashwood其他文献

Roderick H Dashwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roderick H Dashwood', 18)}}的其他基金

Immunoepigenetic targeting of MHC regulators in FAP
FAP 中 MHC 调节因子的免疫表观遗传学靶向
  • 批准号:
    10677375
  • 财政年份:
    2023
  • 资助金额:
    $ 3.41万
  • 项目类别:
CCAR2 as a Target for Prevention of Colorectal Cancer.
CCAR2 作为预防结直肠癌的靶点。
  • 批准号:
    10565953
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
CCAR2 as a Target for Prevention of Colorectal Cancer.
CCAR2 作为预防结直肠癌的靶点。
  • 批准号:
    10358583
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
  • 批准号:
    8009888
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
  • 批准号:
    7595928
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
  • 批准号:
    7456211
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
  • 批准号:
    8213687
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
  • 批准号:
    7758379
  • 财政年份:
    2008
  • 资助金额:
    $ 3.41万
  • 项目类别:
EFFECT TEA CONSUMP ON PHIP BIOAVIAL AT ULTR-LOW DOSE IN HUMAN VOL
超低剂量的茶摄入量对人体体积中 PHIP 生物病毒的影响
  • 批准号:
    7602424
  • 财政年份:
    2007
  • 资助金额:
    $ 3.41万
  • 项目类别:
Chemoprevention of Colon Cancer, HDAC Inhibition, and Histone Status
结肠癌的化学预防、HDAC 抑制和组蛋白状态
  • 批准号:
    8288253
  • 财政年份:
    2003
  • 资助金额:
    $ 3.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了